IN THE CLAIMS:

Please add new claims 78-95.

Please cancel claims 1-31, 35-50 and 52-77 without prejudice.

Please amend claims 32-34 and 51 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-31 **(Cancelled)**

32. **(Currently amended)** A method for screening for anticancer activity in a potential drug, the method comprising:

(a) ~~providing~~ contacting a cell that expresses a cancer associated (CA) gene ~~encoded by~~ comprising a nucleic acid sequence of SEQ ID NO:776 with a candidate anticancer drug ~~selected from the group consisting of the sequences hD07-001 through hD07-128 shown in Tables 1-128 or fragment thereof~~; and

(b) ~~contacting a tissue sample derived from a cancer cell with an anticancer drug candidate; and~~ ~~(c)~~ monitoring an effect of the ~~anticancer drug~~ candidate anticancer drug on ~~an~~ expression of the CA gene ~~in the tissue sample~~,

wherein a candidate drug that alters expression of the CA gene is identified as a drug with anticancer activity.

33. **(Currently amended)** The method of screening for anticancer activity according to claim 32, wherein the CA gene ~~comprises at least one~~ encodes a nucleic acid comprising ~~sequence~~ SEQ ID NO:777 ~~selected from the group consisting of the sequences hR07-001 through hR07-128~~.

34. **(Currently amended)** The method of screening for anticancer activity according

to claim 32, further comprising: ~~(d)~~ (c) comparing the level of expression of the CA gene in the absence of said drug candidate to the level of expression of the CA gene in the presence of the drug candidate.

Claims 35-50 **(Cancelled)**

51. **(Currently amended)** A method for diagnosing cancer comprising: a) determining the expression of ~~one or more genes~~ a gene which encodes a ~~comprising a~~ nucleic acid ~~sequence~~ comprising SEQ ID NO:777 ~~selected from the group consisting of the sequences outlined in Tables 1-128~~, in a first tissue type of a first individual; and b) comparing said expression of said ~~gene(s)~~ gene from a second normal tissue type from said first individual or a second unaffected individual; wherein a difference in said expression indicates that the first individual has cancer.

Claims 52-77 **(Cancelled)**

78. **(New)** A method for diagnosing colon, breast or prostate cancer comprising comparing a level of myosin I mRNA in a patient sample comprising colon, breast or prostate tissue to the level of the myosin I mRNA in a normal control; wherein a change of at least 50% in the level in the patient sample relative to the normal control indicates that the patient has or is predisposed to colon, breast or prostate cancer.

79. **(New)** The method of claim 78 wherein the mRNA comprises a nucleotide sequence at least 95% identical to SEQ ID NO:777, said mRNA encoding an actin binding motor protein.

80. **(New)** The method of claim 78 wherein the mRNA comprises a nucleotide sequence at least 98% identical to SEQ ID NO: 777, said mRNA encoding an actin binding motor protein.

81. **(New)** The method of claim 78 wherein the mRNA comprises SEQ ID NO: 777.

82. **(New)** The method of claim 78 wherein a change of at least 100% in the level of the myosin I mRNA in the patient sample relative to the normal control indicates that the patient has or is predisposed to colon, breast or prostate cancer.

83. **(New)** A method for diagnosing colon, breast or prostate cancer comprising detecting evidence of differential expression of myosin I in a patient sample, wherein evidence of differential expression of myosin I indicates that the patient has colon, breast or prostate cancer.

84. **(New)** The method of claim 83 wherein evidence of differential expression is detected by measuring the level of an expression product of myosin I.

85. **(New)** The method of claim 84 wherein the expression product is a protein or mRNA.

86. **(New)** The method of claim 85 wherein the level of expression of protein is measured using an antibody which specifically binds to a myosin I polypeptide.

87. **(New)** The method of claim 86 wherein the antibody is linked to an imaging agent.

88. **(New)** The method of claim 84 wherein the level of a myosin I expression product in the patient sample is compared to a control.

89. **(New)** The method of claim 88 wherein the control comprises normal colon, breast or prostate tissue.

90. **(New)** The method of claim 88 wherein the level of the expression product in the patient sample is changed by at least 200% relative to the control.

91. **(New)** The method of claim 83 wherein evidence of differential expression is detected by measuring the level of a myosin I expression product at least 95% identical to SEQ ID NO: 777, said expression product encoding an actin binding motor protein.

92. **(New)** The method of claim 83 wherein evidence of differential expression is detected by measuring the level of a myosin I expression product at least 98% identical to SEQ ID NO: 777, said expression product encoding an actin binding motor protein.

93. **(New)** The method of claim 83 wherein evidence of differential expression is detected by measuring the level of a myosin I expression product comprising SEQ ID NO: 777.

94. **(New)** A method of diagnosing colon, breast or prostate cancer in a patient comprising:

(a) contacting a polynucleotide that hybridizes under highly stringent conditions to a nucleotide sequence comprising SEQ ID NO: 777 with nucleic acids of a patient colon, breast or prostate sample under binding conditions suitable to form a duplex; and

(b) comparing the amount of the duplex formed to the amount of duplex formed when the polynucleotide is contacted with nucleic acids of a non-cancerous colon, breast or prostate control,

wherein altered levels of the amount of duplex formed upon contacting said polynucleotide with said nucleic acids of the patient sample compared to the amount of duplex formed upon contacting said polynucleotide and said nucleic acids of the non-cancerous control indicates that the patient has colon, breast or prostate cancer.

95. (**New**) The method of claim 94 wherein hybridization is performed at 60°C in 5 X SSC (9 mM saline /0.9 mM sodium citrate).